2021
Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis
Szymczak F, Colli M, Mamula M, Evans-Molina C, Eizirik D. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Science Advances 2021, 7: eabd7600. PMID: 33523973, PMCID: PMC7787485, DOI: 10.1126/sciadv.abd7600.Peer-Reviewed Original ResearchConceptsType 1 diabetesLupus erythematosusTarget tissuesRheumatoid arthritisMultiple sclerosisAutoimmune diseasesImmune systemSystemic lupus erythematosusTarget tissue levelRepurposing of drugsDisease-specific signaturesGene expression signaturesImmune assaultSimilar molecular signaturesClinical useTissue levelsDiseaseHigh expressionExpression signaturesDifferent diseasesErythematosusArthritisSclerosisDiabetesTherapy
2013
Identification of posttranslational modified autoantigens in Type 1 diabetes. (P4152)
Yang M, Connolly S, Wen L, Herold K, Mamula M. Identification of posttranslational modified autoantigens in Type 1 diabetes. (P4152). The Journal Of Immunology 2013, 190: 172.3-172.3. DOI: 10.4049/jimmunol.190.supp.172.3.Peer-Reviewed Original ResearchNOD miceType 1 diabetesDiabetes-prone NOD miceEarly-onset diabetic patientsPre-diabetic NOD miceDiabetic NOD miceT cell autoimmunityPathogenesis of T1DPancreatic islet proteinsCell autoimmunityDiabetic patientsImmune toleranceRheumatoid arthritisMultiple sclerosisAutoimmune diseasesMurine modelTarget organsTherapeutic targetSelf proteinsPancreatic isletsIslet proteinsMiceOxidative stressPeripheral erythrocytesDiabetes